🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07737496
Recruiting Phase 1

A Study of HW243040 in Healthy Participants

NCT07737496 · tracked via the Priya Life Science China tracker
Sponsor
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase
Phase 1
Started
2026-08-20
Last updated
2026-08-27

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

HW243040Placebo

HW243040: HW243040 will be administered orally as a tablet.

Placebo: Placebo will be administered orally as a tablet.

Study summary

This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Informed consent must be obtained/signed prior to trial participation. * Aged between 18 and 55 years old, both healthy males and females are eligible. * Female participates must have a body weight of ≥ 45 kg and male participates ≥ 50 kg, with a body mass index (BMI) ranging from 19 to 26 kg/m\^2. Exclusion Criteria: * History or presence of any clinically severe disorders of urinary, cardiovascular, endocrine, nervous, gastrointestinal, respiratory, hematologic, immune systems, psychiatric illnesses or metabolic abnormalities; or other conditions judged by the Investigator to confound trial outcomes, e.g., intestinal diseases (irritable bowel syndrome), urinary tract infections. * History of malignant tumors (except for cancer with confirmed cure or remission for ≥5 years, radically resected basal or squamous cell skin cancer, carcinoma in situ of the cervix, and resected colonic polyps). * Any conditions or diseases that, in the Investigator's judgment, may affect the absorption, metabolism and/or excretion of the investigational product. * History of drug abuse or dependence. * Hypersensitivity to any ingredient of the study drug,or history of allergic disorders or allergic diathesis. * Any other condition that, in the opinion of the investigator, renders the participant unsuitable to participate in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Third Xiangya Hospital of Central South University Changsha Hunan Recruiting

More Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07737496 on ClinicalTrials.gov ↗ ← All trials in China